Category News

NICE Recommends Ebglyss for Moderate to Severe Atopic Dermatitis Treatment in NHS England for Eligible Adolescents and Adults

Lebrikizumab has been approved for treating moderate-to-severe atopic dermatitis in adolescents (12 years and older) and adults who require systemic therapy. This treatment received approval from the European Commission and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in…

Read MoreNICE Recommends Ebglyss for Moderate to Severe Atopic Dermatitis Treatment in NHS England for Eligible Adolescents and Adults

CytoTronics Advances Live Cell Monitoring and Introduces Pixel Octo for High-Throughput Cell Biology Discovery

This new addition to the Pixel lineup integrates the company’s semiconductor-to-live-cell interface in an environmental controlled benchtop system to deliver live cell measurements for up to eight 96-well Pixel plates simultaneously. When paired with laboratory robotic automation, the Pixel Octo…

Read MoreCytoTronics Advances Live Cell Monitoring and Introduces Pixel Octo for High-Throughput Cell Biology Discovery

Precision Neuromodulation Reduces Brain Atrophy and Boosts Connectivity in Alzheimer’s Patients

Sinaptica, a clinical-stage company pioneering personalized neuromodulation therapies for Alzheimer’s and other neurodegenerative diseases, has announced the publication of a study in Alzheimer’s Research & Therapy. The study utilized MRI and fMRI neuroimaging to assess structural and connectivity changes in…

Read MorePrecision Neuromodulation Reduces Brain Atrophy and Boosts Connectivity in Alzheimer’s Patients

Adicet Bio Secures FDA Fast Track Designation for ADI-270 in Advanced Metastatic Clear Cell Renal Cell Carcinoma

Adicet Bio, a clinical-stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-270. This designation is for…

Read MoreAdicet Bio Secures FDA Fast Track Designation for ADI-270 in Advanced Metastatic Clear Cell Renal Cell Carcinoma

Navidea Biopharmaceuticals, Inc. Releases Findings from Exploratory Analysis Conducted on July 2, 2024

Navidea Biopharmaceuticals, Inc. a company specializing in precision immunodiagnostic agents and immunotherapeutics, has disclosed disappointing findings from an exploratory analysis conducted on its pivotal NAV3-33 clinical trial, titled “Evaluation of Tc 99m Tilmanocept Imaging for the Early Prediction of Anti-TNFα…

Read MoreNavidea Biopharmaceuticals, Inc. Releases Findings from Exploratory Analysis Conducted on July 2, 2024